- Clinical Trials
- April 2024
- 60 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Report
- March 2024
- 197 Pages
Global
From €3262EUR$3,374USD£2,804GBP
€3624EUR$3,749USD£3,115GBP
- Report
- March 2024
- 200 Pages
Global
From €4012EUR$4,150USD£3,448GBP
- Report
- April 2023
- 137 Pages
Global
From €7250EUR$7,500USD£6,232GBP
- Report
- January 2022
- 200 Pages
Global
From €7250EUR$7,500USD£6,232GBP
- Report
- January 2022
- 60 Pages
Global
From €3819EUR$3,950USD£3,282GBP
- Report
- February 2022
- 120 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- June 2021
- 120 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- March 2022
- 41 Pages
Global
From €3379EUR$3,495USD£2,904GBP
- Drug Pipelines
- August 2020
- 868 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Report
- August 2023
- 98 Pages
Global
From €3500EUR$3,878USD£3,114GBP
- Report
- April 2022
- 316 Pages
Global
From €2417EUR$2,500USD£2,077GBP
Osteosarcoma is a type of cancer that affects the bones, most commonly found in children and young adults. Oncology drugs are used to treat this type of cancer, and the Osteosarcoma Drug market is a subset of the larger Oncology Drug market. These drugs are used to reduce the size of tumors, reduce pain, and improve quality of life. Treatment options include chemotherapy, radiation therapy, and surgery.
The Osteosarcoma Drug market is highly competitive, with many companies developing and marketing drugs to treat this type of cancer. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and Eli Lilly. Other companies such as Amgen, AstraZeneca, and GlaxoSmithKline are also active in the market. Show Less Read more
